Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048099 · ClinicalTrials.gov registry record · NA
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
A NA study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- NA
- Development phase
- 283
- Enrollment target
NCT01048099 is a NA study that has completed, run by SCRI Development Innovations. The registered enrollment target is 283 participants.
The verdict
NCT01048099, a NA study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- NA
- Development phase
- 283 participants
- Enrollment target
Study Summary
This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2 overexpression/activation by the PRO Onc Assay.
Interventions
- DRUG Trastuzumab
- DRUG Pertuzumab
- PROCEDURE PRO Onc Assay and Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01048099
The ClinicalTrials.gov registry entry for NCT01048099 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT01048099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01048099 about?
NCT01048099 is a clinical study titled "Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer". This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2 overexpression/activation by the PRO Onc Assay.
What is the current status of trial NCT01048099?
This trial is currently completed. It is a NA study. The enrollment target is 283 participants. The study started on 2011-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01048099?
The interventions under investigation include: Trastuzumab (DRUG), Pertuzumab (DRUG), PRO Onc Assay and Treatment (PROCEDURE).
Who is sponsoring clinical trial NCT01048099?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.